Waystar: Bullish Article Highlights Growth, But Valuation and Leverage Keep Stance Neutral

What happened

A bullish Seeking Alpha article rates Waystar a Buy with 85% upside to $37, citing 22% revenue growth, 40%+ margins, a $200M buyback, and AI-driven expansion. The article highlights the Iodine acquisition and AltitudeAI suite as catalysts in a $100B+ market, with 23 of 24 analysts bullish. However, the DeepValue master report maintains a WAIT stance, noting the stock trades at ~58x P/E and ~13.5x EV/EBITDA, 66% above a DCF estimate of $22.32, leaving limited margin of safety. The report also cautions about net debt/EBITDA of 3.5x, interest coverage of 3.3x, and competitive/regulatory risks. While the article's growth narrative is compelling, the elevated valuation and leverage imply the stock is priced for perfection, and flawless execution is required to justify current levels.

Implication

The article reinforces Waystar's strong growth trajectory and market position, but the DeepValue report's caution on valuation and leverage is well-founded. At current multiples, the stock is priced for perfection, and any misstep—on integration, security, or growth—could lead to significant downside. Investors should monitor quarterly results for sustained revenue growth above 20%, net revenue retention above 110%, and progress on deleveraging. A pullback to the DCF range of $22-25 would offer a better risk-reward, as would evidence of operating leverage and reduced leverage. Until then, the prudent stance is to wait.

Thesis delta

The bullish Seeking Alpha article does not alter the fundamental thesis: Waystar is a high-quality healthcare RCM platform with strong growth, but the current valuation and leverage limit upside potential and increase downside risk. The article's enthusiasm is justified by the business quality, but the DCF-implied discount and high multiples suggest the market has already priced in a best-case scenario. The thesis remains WAIT, as the risk-reward is balanced but favors waiting for either a lower price or clearer evidence of sustained outperformance and deleveraging.